FamiCord（V3V）株式概要FamiCord AGは、ドイツ、ポーランド、ポルトガル、そして世界各国において、臍帯血や組織、出生後組織からの幹細胞の収集、加工、凍結保存、保管に従事している。 詳細V3V ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長4/6過去の実績0/6財務の健全性2/6配当金0/6報酬当社が推定した公正価値より64.7%で取引されている 収益は年間104.37%増加すると予測されています 同業他社や業界と比較して、良好な取引価格 リスク分析意味のある時価総額がありません ( €69M )すべてのリスクチェックを見るV3V Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN47.1% undervaluedAnalystConsensusTarget•5mo agoPlacenta Banking Expansion Will Drive Long Term Stem Cell Demand Across Europe501Top Analyst NarrativesFamiCordANAnalystConsensusTargetBased on Analyst Price TargetsPlacenta Banking Expansion Will Drive Long Term Stem Cell Demand Across EuropeCatalysts About FamiCord FamiCord operates private and public stem cell and placenta banks across Europe, storing biological samples from newborns for future therapeutic use. What are the underlying business or industry changes driving this perspective?View narrative€7.5FV47.1% 割安 内在価値ディスカウントSet Fair ValueView5users have viewed this narrative0users have liked this narrative0users have commented on this narrative1users have followed this narrative6 months ago author updated this narrativeView all narrativesFamiCord AG 競合他社LIMES SchlossklinikenSymbol: XTRA:LIKMarket cap: €154.9mMEDICLINSymbol: XTRA:MEDMarket cap: €177.7mDocCheckSymbol: XTRA:AJ91Market cap: €66.0mMaternus-KlinikenSymbol: XTRA:MAKMarket cap: €21.2m価格と性能株価の高値、安値、推移の概要FamiCord過去の株価現在の株価€3.9752週高値€7.6552週安値€3.80ベータ0.631ヶ月の変化-10.59%3ヶ月変化-22.16%1年変化-3.64%3年間の変化-38.35%5年間の変化-76.65%IPOからの変化-69.03%最新ニュースお知らせ • May 30FamiCord AG Confirms Earnings Guidance for 2026FamiCord AG confirmed earnings guidance for 2026. The Management Board confirms its guidance for the 2026 financial year, expecting revenues in a range of EUR 80 million to EUR 90 million.お知らせ • May 14FamiCord AG, Annual General Meeting, Jun 24, 2026FamiCord AG, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time.Reported Earnings • May 05Full year 2025 earnings released: €0.26 loss per share (vs €0.70 loss in FY 2024)Full year 2025 results: €0.26 loss per share (improved from €0.70 loss in FY 2024). Revenue: €88.2m (up 7.3% from FY 2024). Net loss: €4.61m (loss narrowed 62% from FY 2024). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.New Risk • May 03New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€77.4m market cap, or US$90.7m).New Risk • Mar 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €83.3m (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.分析記事 • Jan 28Is FamiCord (ETR:V3V) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...最新情報をもっと見るRecent updatesお知らせ • May 30FamiCord AG Confirms Earnings Guidance for 2026FamiCord AG confirmed earnings guidance for 2026. The Management Board confirms its guidance for the 2026 financial year, expecting revenues in a range of EUR 80 million to EUR 90 million.お知らせ • May 14FamiCord AG, Annual General Meeting, Jun 24, 2026FamiCord AG, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time.Reported Earnings • May 05Full year 2025 earnings released: €0.26 loss per share (vs €0.70 loss in FY 2024)Full year 2025 results: €0.26 loss per share (improved from €0.70 loss in FY 2024). Revenue: €88.2m (up 7.3% from FY 2024). Net loss: €4.61m (loss narrowed 62% from FY 2024). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.New Risk • May 03New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€77.4m market cap, or US$90.7m).New Risk • Mar 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €83.3m (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.分析記事 • Jan 28Is FamiCord (ETR:V3V) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...お知らせ • Dec 24+ 3 more updatesFamiCord AG to Report Q3, 2026 Results on Nov 23, 2026FamiCord AG announced that they will report Q3, 2026 results on Nov 23, 2026分析記事 • Dec 13FamiCord AG (ETR:V3V) Stock Rockets 28% As Investors Are Less Pessimistic Than ExpectedFamiCord AG ( ETR:V3V ) shares have had a really impressive month, gaining 28% after a shaky period beforehand. Looking...Reported Earnings • Nov 23Third quarter 2025 earnings released: EPS: €0.074 (vs €0.06 in 3Q 2024)Third quarter 2025 results: EPS: €0.074 (up from €0.06 in 3Q 2024). Revenue: €22.8m (up 2.5% from 3Q 2024). Net income: €1.24m (up 14% from 3Q 2024). Profit margin: 5.4% (up from 4.9% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.お知らせ • Nov 22FamiCord AG Confirms Earnings Guidance for the Financial Year 2025FamiCord AG confirmed earnings guidance for the financial year 2025. On the basis of the performance in the first nine months of 2025, the Management Board looks to the remaining months of the year with confidence. The combination of solid revenue growth with attractive gross margins, a strong improvement in EBITDA, a positive operating cash flow despite the shift towards recurring revenues and a stable financial position provides a robust foundation. Against this backdrop, the Management Board confirms its outlook for the full year 2025, which continues to assume revenues of between EUR 85 million and EUR 95 million.分析記事 • Sep 23Is FamiCord (ETR:V3V) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Price Target Changed • Sep 03Price target increased by 19% to €7.50Up from €6.30, the current price target is provided by 1 analyst. New target price is 10% above last closing price of €6.80. Stock is up 45% over the past year. The company is forecast to post earnings per share of €0.04 next year compared to a net loss per share of €0.70 last year.分析記事 • Aug 26Subdued Growth No Barrier To FamiCord AG (ETR:V3V) With Shares Advancing 33%Despite an already strong run, FamiCord AG ( ETR:V3V ) shares have been powering on, with a gain of 33% in the last...New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.分析記事 • Jul 10FamiCord AG (ETR:V3V) Stocks Shoot Up 26% But Its P/S Still Looks ReasonableFamiCord AG ( ETR:V3V ) shares have continued their recent momentum with a 26% gain in the last month alone. Taking a...お知らせ • May 16FamiCord AG, Annual General Meeting, Jun 25, 2025FamiCord AG, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time.Price Target Changed • May 06Price target increased by 8.3% to €6.50Up from €6.00, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €3.94. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.01 next year compared to a net loss per share of €0.70 last year.Reported Earnings • May 04Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: €0.70 loss per share (further deteriorated from €0.12 loss in FY 2023). Revenue: €82.2m (up 6.6% from FY 2023). Net loss: €12.1m (loss widened €10.3m from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • Jan 09+ 3 more updatesVITA 34 AG to Report Q1, 2025 Results on May 28, 2025VITA 34 AG announced that they will report Q1, 2025 results on May 28, 2025Major Estimate Revision • Dec 01Consensus estimates of losses per share improve by 38%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €81.0m to €82.0m. EPS estimate increased from -€0.08 per share to -€0.05 per share. Healthcare industry in Germany expected to see average net income decline 4.2% next year. Consensus price target of €6.30 unchanged from last update. Share price was steady at €4.12 over the past week.New Risk • Nov 25New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 17% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€72.5m market cap, or US$75.5m).Reported Earnings • Sep 01Second quarter 2024 earnings released: €0.10 loss per share (vs €0.07 loss in 2Q 2023)Second quarter 2024 results: €0.10 loss per share (further deteriorated from €0.07 loss in 2Q 2023). Revenue: €19.5m (up 6.0% from 2Q 2023). Net loss: €1.41m (loss widened 19% from 2Q 2023). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.Major Estimate Revision • Jun 09Consensus estimates of losses per share improve by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €79.1m to €81.0m. EPS estimate increased from -€0.12 per share to -€0.08 per share. Healthcare industry in Germany expected to see average net income growth of 16% next year. Consensus price target up from €5.30 to €6.00. Share price rose 3.0% to €4.86 over the past week.Reported Earnings • Jun 05First quarter 2024 earnings released: €0.05 loss per share (vs €0.18 loss in 1Q 2023)First quarter 2024 results: €0.05 loss per share (improved from €0.18 loss in 1Q 2023). Revenue: €18.6m (up 3.6% from 1Q 2023). Net loss: €785.0k (loss narrowed 73% from 1Q 2023). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.Price Target Changed • Jun 05Price target increased by 15% to €6.00Up from €5.21, the current price target is provided by 1 analyst. New target price is 22% above last closing price of €4.92. Stock is down 20% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.12 last year.Breakeven Date Change • May 02No longer forecast to breakevenThe analyst covering VITA 34 no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.05m in 2024. New forecast suggests the company will make a loss of €1.50m in 2025.お知らせ • Apr 27+ 3 more updatesVITA 34 AG to Report Q1, 2024 Results on May 31, 2024VITA 34 AG announced that they will report Q1, 2024 results on May 31, 2024New Risk • Apr 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€78.8m market cap, or US$83.8m).New Risk • Apr 04New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €25m Forecast net loss in 2 years: €1.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Shareholders have been diluted in the past year (10% increase in shares outstanding).分析記事 • Apr 04Why We're Not Concerned About VITA 34 AG's (ETR:V3V) Share PriceWhen close to half the companies in the Healthcare industry in Germany have price-to-sales ratios (or "P/S") below...New Risk • Feb 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€86.3m market cap, or US$93.1m).分析記事 • Dec 24Revenues Tell The Story For VITA 34 AG (ETR:V3V) As Its Stock Soars 26%VITA 34 AG ( ETR:V3V ) shareholders would be excited to see that the share price has had a great month, posting a 26...Reported Earnings • Nov 26Third quarter 2023 earnings released: €0.10 loss per share (vs €0.02 loss in 3Q 2022)Third quarter 2023 results: €0.10 loss per share (further deteriorated from €0.02 loss in 3Q 2022). Revenue: €20.4m (up 9.4% from 3Q 2022). Net loss: €1.62m (loss widened €1.41m from 3Q 2022). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 1.6% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.分析記事 • Nov 23Is VITA 34 (ETR:V3V) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Sep 01Second quarter 2023 earnings released: €0.07 loss per share (vs €0.30 loss in 2Q 2022)Second quarter 2023 results: €0.07 loss per share (improved from €0.30 loss in 2Q 2022). Revenue: €18.4m (up 10% from 2Q 2022). Net loss: €1.19m (loss narrowed 74% from 2Q 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.分析記事 • Jul 15Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Major Estimate Revision • Jul 05Consensus EPS estimates fall by 28%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €75.0m to €76.0m. Forecast EPS reduced from -€0.09 to -€0.115 per share. Healthcare industry in Germany expected to see average net income growth of 15% next year. Consensus price target down from €9.25 to €6.81. Share price rose 2.2% to €5.64 over the past week.New Risk • Jun 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€83.6m market cap, or US$91.2m).New Risk • Jun 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €83.6m (US$90.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Reported Earnings • Jun 02First quarter 2023 earnings released: €0.18 loss per share (vs €0.18 loss in 1Q 2022)First quarter 2023 results: €0.18 loss per share (in line with 1Q 2022). Revenue: €17.9m (up 16% from 1Q 2022). Net loss: €2.89m (loss widened 2.8% from 1Q 2022). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance.お知らせ • May 12Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug CandidateVita 34 AG has started enrollment in Phase I of the Tarcidomgen Kimleucel clinical trial. The drug candidate is an anti-CD19 CAR-T, a chimeric antigen receptor, and the first candidate in Vita 34's Cell & Gene Therapy (CGT) portfolio. After recent clearance by the responsible authorities and the responsible ethics committee, the start of the clinical trial under the name CARLA and the recruitment of the first patient ("First Patient In") is imminent. A total of up to ten patients are expected to be recruited for Phase I of the study, which is the usual number for this type of drug. The recruitment will take place via two clinical centers in Poland. The Management Board of Vita 34 AG expects Phase I to be completed by the end of 2023. The costs related with this phase of the trial have already taken into consideration in the guidance published for 2023. The principal investigator of the CARLA study is Prof. Grzegorz Basak, Professor and Chairman of the Department of Hematology, Transplantation and Internal Medicine at the University Hospital of Warsaw Medical University. Tarcidomgen Kimlucel is being developed through FamiCordTx, a subsidiary of Vita 34 AG that aims to develop proprietary CAR-T drug therapies. FamiCordTx has secured an exclusive license from a U.S. supplier for this purpose in the past and has optimized the technology according to European GMP standards. CAR-T therapy uses a patient's own T cells, which are genetically engineered in a laboratory to produce a protein called a chimeric antigen receptor (CAR). When the modified T-cells are returned to the patient, the CAR enables the T- cells to seek out and destroy cancer cells wherever they are in the body. According to a report by Allied Market Research, the global CAR-T cell therapy market was valued USD 1,7 billion in 2021 and is expected to reach USD 6.1 billion by 2031.Reported Earnings • May 02Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: €1.71 loss per share (further deteriorated from €0.63 loss in FY 2021). Revenue: €68.9m (up 143% from FY 2021). Net loss: €27.1m (loss widened €23.4m from FY 2021). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 100 percentage points per year, which is a significant difference in performance.分析記事 • Feb 17Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...お知らせ • Dec 03+ 4 more updatesVITA 34 AG to Report Q3, 2023 Results on Nov 21, 2023VITA 34 AG announced that they will report Q3, 2023 results on Nov 21, 2023Major Estimate Revision • Dec 01Consensus estimates of losses per share improve by 10%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from €66.5m to €67.7m. EPS estimate increased from -€0.59 per share to -€0.53 per share. Healthcare industry in Germany expected to see average net income decline 6.2% next year. Consensus price target of €10.50 unchanged from last update. Share price fell 7.6% to €8.32 over the past week.Reported Earnings • Nov 24Third quarter 2022 earnings released: €0.02 loss per share (vs €0.11 profit in 3Q 2021)Third quarter 2022 results: €0.02 loss per share (down from €0.11 profit in 3Q 2021). Revenue: €18.7m (up 230% from 3Q 2021). Net loss: €209.0k (down 147% from profit in 3Q 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.Price Target Changed • Nov 16Price target decreased to €10.50Down from €12.50, the current price target is an average from 2 analysts. New target price is 17% above last closing price of €9.00. Stock is down 46% over the past year. The company is forecast to post a net loss per share of €0.59 next year compared to a net loss per share of €0.63 last year.Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: €0.30 (vs €0.002 loss in 2Q 2021)Second quarter 2022 results: EPS: €0.30. Revenue: €16.6m (up 206% from 2Q 2021). Net loss: €4.61m (loss widened €4.60m from 2Q 2021). Over the next year, revenue is forecast to grow 48%, compared to a 3.7% growth forecast for the Healthcare industry in Germany.お知らせ • Aug 31VITA 34 AG Revises Earnings Guidance for the Financial Year 2022VITA 34 AG revised earnings guidance for the financial year 2022. For the year, the company adjusting the forecast ranges for consolidated sales to EUR 65 to EUR 72 million (previously: EUR 68 to EUR 75 million).お知らせ • Aug 24VITA 34 AG to Report Q2, 2022 Results on Aug 30, 2022VITA 34 AG announced that they will report Q2, 2022 results on Aug 30, 2022お知らせ • Jun 30+ 1 more updateVITA 34 AG, Annual General Meeting, Jun 29, 2022VITA 34 AG, Annual General Meeting, Jun 29, 2022. Agenda: To consider new Chief Financial Officer; and to consider other matters.Major Estimate Revision • Jun 07Consensus EPS estimates fall by 85%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €73.4m to €68.9m. Losses expected to increase from €0.27 per share to €0.50. Healthcare industry in Germany expected to see average net income growth of 6.5% next year. Consensus price target down from €14.00 to €13.00. Share price rose 2.3% to €11.35 over the past week.Reported Earnings • Jun 02First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: €0.18 loss per share (down from €0.01 loss in 1Q 2021). Revenue: €15.5m (up 188% from 1Q 2021). Net loss: €2.81m (loss widened €2.77m from 1Q 2021). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 103%, compared to a 4.8% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.お知らせ • May 25VITA 34 AG to Report Q1, 2022 Results on May 31, 2022VITA 34 AG announced that they will report Q1, 2022 results on May 31, 2022Reported Earnings • May 02Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: €0.63 loss per share (down from €0.37 profit in FY 2020). Revenue: €28.4m (up 42% from FY 2020). Net loss: €3.67m (down 343% from profit in FY 2020). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 17% compared to a 5.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • May 02Vita 34 Ag Provides Revenue Guidance for the Financial Year 2022VITA 34 AG provided revenue guidance for the financial year 2022. For the year, the company expects consolidated revenues of between EUR 68 million and EUR 75 million for the full year 2022 (2021: EUR 28.4 million).Price Target Changed • Apr 27Price target increased to €25.00Up from €19.10, the current price target is provided by 1 analyst. New target price is 109% above last closing price of €11.95. Stock is down 29% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year.分析記事 • Apr 08Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?VITA 34 AG ( ETR:V3V ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in the...Price Target Changed • Dec 18Price target increased to €21.10Up from €19.10, the current price target is an average from 2 analysts. New target price is 35% above last closing price of €15.60. Stock is up 27% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year.分析記事 • Dec 07VITA 34 AG's (ETR:V3V) CEO Compensation Looks Acceptable To Us And Here's WhyDespite strong share price growth of 39% for VITA 34 AG ( ETR:V3V ) over the last few years, earnings growth has been...Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS €0.14 (vs €0.18 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: €5.82m (up 7.4% from 3Q 2020). Net income: €575.0k (down 23% from 3Q 2020). Profit margin: 9.9% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Reported Earnings • Sep 01Second quarter 2021 earnings releasedThe company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: €5.44m (up 11% from 2Q 2020). Net loss: €12.0k (down 102% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 3% per year.Major Estimate Revision • Jun 08Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from €22.0m to €21.8m. EPS estimate rose from €0.47 to €0.52. Net income forecast to grow 92% next year vs 92% growth forecast for Healthcare industry in Germany. Consensus price target of €19.10 unchanged from last update. Share price was steady at €17.05 over the past week.お知らせ • Jun 02VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million.VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million on May 31, 2021. Transaction to be carried out by way of a contribution in kind at an exchange of 1.3 new Vita 34 shares in exchange for one (1) share of PBKM. Under the transaction, AOC Health GmbH will sell 5.743221 million shares representing 62.4% stake, Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. will sell 1.282201 million shares representing 13.93% stake and Jakub Baran will sell 0.395875 million shares representing 4.3% stake. Major PBKM shareholders have already agreed to contribute to Vita 34 a total of 6.363170 million PBKM shares (representing approximately 69.13% of the current share capital of PBKM). The combined Group will be listed on the Frankfurt Stock Exchange, with Vita 34 as the listed parent company. These shareholders include (inter alia) AOC Health GmbH, Jakub Baran, President and Chief Executive officer of the PBKM Management Board, and Tomasz Baran, Vice President and Deputy Chief Executive officer of the PBKM Management Board. The new Vita 34 shares to be issued under the Proposed Transaction shall be created by way of a capital increase in kind still to be resolved upon by Vita 34’s shareholders. For purposes of resolving the capital increase, Vita 34 will convene an extraordinary general meeting for July 13, 2021, with the ordinary annual general meeting originally scheduled for June 30, 2021 to be postponed and likely to take place in the fourth quarter of 2021. At the extraordinary general meeting, Vita 34’s share capital shall be increased by up to €12.280560 million against contribution in kind by issuing up to 12,280,560 no-par value registered shares. Completion of the Exchange Offer is subject to a number of conditions, including the achievement of a minimum acceptance level of 95% of PBKM’s outstanding shares and the absence of any material adverse change and no material adverse infringements occurring at PBKM. Transaction has been approved by the Supervisory Board of Vita 34 AG. The Management Board PBKM intends to support the Proposed Transaction and recommend to the PBKM shareholders to accept the Exchange Offer. Transaction is expected to complete by the end of October 2021. VITA 34 AG appointed ValueTrust Financial Advisors SE as an independent expert under the transaction.Reported Earnings • Jun 01First quarter 2021 earnings releasedThe company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: €5.38m (up 15% from 1Q 2020). Net loss: €38.0k (down 110% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.お知らせ • Jun 01VITA 34 AG Provides Earnings Guidance for the Year 2021VITA 34 AG maintained guidance for 2021. The Management Board maintains its guidance for the full fiscal year 2021 of Vita 34 AG (prior to the planned merger) published in the context of the Annual Report 2020.分析記事 • May 12Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?While VITA 34 AG ( ETR:V3V ) might not be the most widely known stock at the moment, it saw a significant share price...Major Estimate Revision • Apr 07Consensus EPS estimates fall to €0.47The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €22.3m to €22.0m. EPS estimate also fell from €0.61 to €0.47. Net income forecast to grow 26% next year vs 16% growth forecast for Healthcare industry in Germany. Consensus price target up from €20.00 to €21.00. Share price rose 2.3% to €15.25 over the past week.分析記事 • Apr 03Earnings Miss: VITA 34 AG Missed EPS By 29% And Analysts Are Revising Their ForecastsVITA 34 AG ( ETR:V3V ) missed earnings with its latest full-year results, disappointing overly-optimistic forecasters...Reported Earnings • Apr 01Full year 2020 earnings released: EPS €0.37 (vs €0.18 in FY 2019)The company reported a solid full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: €20.1m (flat on FY 2019). Net income: €1.51m (up 104% from FY 2019). Profit margin: 7.5% (up from 3.7% in FY 2019). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.分析記事 • Mar 25VITA 34 AG's (ETR:V3V) Intrinsic Value Is Potentially 56% Above Its Share PriceHow far off is VITA 34 AG ( ETR:V3V ) from its intrinsic value? Using the most recent financial data, we'll take a look...お知らせ • Mar 17+ 3 more updatesVITA 34 AG to Report Q1, 2021 Results on May 11, 2021VITA 34 AG announced that they will report Q1, 2021 results on May 11, 2021分析記事 • Mar 10Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...分析記事 • Feb 22Here's Why VITA 34 (ETR:V3V) Can Manage Its Debt ResponsiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 10New 90-day high: €13.95The company is up 11% from its price of €12.60 on 11 November 2020. The German market is also up 11% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Healthcare industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.83 per share.分析記事 • Feb 05Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?VITA 34 AG ( ETR:V3V ), might not be a large cap stock, but it led the XTRA gainers with a relatively large price hike...Is New 90 Day High Low • Jan 23New 90-day high: €13.05The company is up 4.0% from its price of €12.55 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.88 per share.分析記事 • Jan 18Can Mixed Financials Have A Negative Impact on VITA 34 AG's 's (ETR:V3V) Current Price Momentum?Most readers would already know that VITA 34's (ETR:V3V) stock increased by 4.5% over the past month. However, we...分析記事 • Jan 02Did You Participate In Any Of VITA 34's (ETR:V3V) Fantastic 201% Return ?The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...お知らせ • Dec 19VITA 34 AG, Annual General Meeting, Jun 30, 2021VITA 34 AG, Annual General Meeting, Jun 30, 2021.分析記事 • Dec 18How Is VITA 34's (ETR:V3V) CEO Compensated?This article will reflect on the compensation paid to Wolfgang Knirsch who has served as CEO of VITA 34 AG ( ETR:V3V...分析記事 • Dec 01Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...株主還元V3VDE HealthcareDE 市場7D-0.3%-4.2%0.7%1Y-3.6%-17.9%2.0%株主還元を見る業界別リターン: V3V過去 1 年間で-17.9 % の収益を上げたGerman Healthcare業界を上回りました。リターン対市場: V3Vは、過去 1 年間で2 % のリターンを上げたGerman市場を下回りました。価格変動Is V3V's price volatile compared to industry and market?V3V volatilityV3V Average Weekly Movement3.1%Healthcare Industry Average Movement6.4%Market Average Movement6.1%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.7%安定した株価: V3V 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: V3Vの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1997766Jakub Baranwww.famicord.comFamiCord AGは、ドイツ、ポーランド、ポルトガル、および国際的な臍帯血や組織、出生後組織からの幹細胞の収集、加工、凍結保存、保管に従事している。サブグループ・ヴィータ34およびサブグループ・PBKMセグメントを通じて事業を展開している。同社は、先進的な治療法、遺伝子検査、第三者向けの分析を製造・開発している。また、医療用の細胞、組織、血液をベースとした製品や医薬品の開発、ウイルスベクターやCAR-T細胞の生産・製造も行っている。さらに、精子の凍結や脂肪組織の保存、保存材料からの細胞の分離などのバイオバンクサービスも提供している。同社は以前はVITA 34 AGとして知られていたが、2025年2月にFamiCord AGに社名を変更した。FamiCord AGは1997年に設立され、ドイツのライプチヒに本社を置いている。もっと見るFamiCord AG 基礎のまとめFamiCord の収益と売上を時価総額と比較するとどうか。V3V 基礎統計学時価総額€69.20m収益（TTM）-€4.61m売上高(TTM)€88.17m0.8xP/Sレシオ-15.0xPER（株価収益率V3V は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計V3V 損益計算書（TTM）収益€88.17m売上原価€36.14m売上総利益€52.03mその他の費用€56.64m収益-€4.61m直近の収益報告Dec 31, 2025次回決算日Aug 28, 2026一株当たり利益（EPS）-0.26グロス・マージン59.01%純利益率-5.22%有利子負債／自己資本比率237.9%V3V の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/31 15:17終値2026/05/29 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋FamiCord AG 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Emily HainesFirst Berlin Equity Research GmbHTim KruseMontega AGUlrich HuwaldWarburg Research GmbH
お知らせ • May 30FamiCord AG Confirms Earnings Guidance for 2026FamiCord AG confirmed earnings guidance for 2026. The Management Board confirms its guidance for the 2026 financial year, expecting revenues in a range of EUR 80 million to EUR 90 million.
お知らせ • May 14FamiCord AG, Annual General Meeting, Jun 24, 2026FamiCord AG, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time.
Reported Earnings • May 05Full year 2025 earnings released: €0.26 loss per share (vs €0.70 loss in FY 2024)Full year 2025 results: €0.26 loss per share (improved from €0.70 loss in FY 2024). Revenue: €88.2m (up 7.3% from FY 2024). Net loss: €4.61m (loss narrowed 62% from FY 2024). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
New Risk • May 03New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€77.4m market cap, or US$90.7m).
New Risk • Mar 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €83.3m (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
分析記事 • Jan 28Is FamiCord (ETR:V3V) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • May 30FamiCord AG Confirms Earnings Guidance for 2026FamiCord AG confirmed earnings guidance for 2026. The Management Board confirms its guidance for the 2026 financial year, expecting revenues in a range of EUR 80 million to EUR 90 million.
お知らせ • May 14FamiCord AG, Annual General Meeting, Jun 24, 2026FamiCord AG, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time.
Reported Earnings • May 05Full year 2025 earnings released: €0.26 loss per share (vs €0.70 loss in FY 2024)Full year 2025 results: €0.26 loss per share (improved from €0.70 loss in FY 2024). Revenue: €88.2m (up 7.3% from FY 2024). Net loss: €4.61m (loss narrowed 62% from FY 2024). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
New Risk • May 03New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€77.4m market cap, or US$90.7m).
New Risk • Mar 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €83.3m (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
分析記事 • Jan 28Is FamiCord (ETR:V3V) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • Dec 24+ 3 more updatesFamiCord AG to Report Q3, 2026 Results on Nov 23, 2026FamiCord AG announced that they will report Q3, 2026 results on Nov 23, 2026
分析記事 • Dec 13FamiCord AG (ETR:V3V) Stock Rockets 28% As Investors Are Less Pessimistic Than ExpectedFamiCord AG ( ETR:V3V ) shares have had a really impressive month, gaining 28% after a shaky period beforehand. Looking...
Reported Earnings • Nov 23Third quarter 2025 earnings released: EPS: €0.074 (vs €0.06 in 3Q 2024)Third quarter 2025 results: EPS: €0.074 (up from €0.06 in 3Q 2024). Revenue: €22.8m (up 2.5% from 3Q 2024). Net income: €1.24m (up 14% from 3Q 2024). Profit margin: 5.4% (up from 4.9% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
お知らせ • Nov 22FamiCord AG Confirms Earnings Guidance for the Financial Year 2025FamiCord AG confirmed earnings guidance for the financial year 2025. On the basis of the performance in the first nine months of 2025, the Management Board looks to the remaining months of the year with confidence. The combination of solid revenue growth with attractive gross margins, a strong improvement in EBITDA, a positive operating cash flow despite the shift towards recurring revenues and a stable financial position provides a robust foundation. Against this backdrop, the Management Board confirms its outlook for the full year 2025, which continues to assume revenues of between EUR 85 million and EUR 95 million.
分析記事 • Sep 23Is FamiCord (ETR:V3V) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Price Target Changed • Sep 03Price target increased by 19% to €7.50Up from €6.30, the current price target is provided by 1 analyst. New target price is 10% above last closing price of €6.80. Stock is up 45% over the past year. The company is forecast to post earnings per share of €0.04 next year compared to a net loss per share of €0.70 last year.
分析記事 • Aug 26Subdued Growth No Barrier To FamiCord AG (ETR:V3V) With Shares Advancing 33%Despite an already strong run, FamiCord AG ( ETR:V3V ) shares have been powering on, with a gain of 33% in the last...
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
分析記事 • Jul 10FamiCord AG (ETR:V3V) Stocks Shoot Up 26% But Its P/S Still Looks ReasonableFamiCord AG ( ETR:V3V ) shares have continued their recent momentum with a 26% gain in the last month alone. Taking a...
お知らせ • May 16FamiCord AG, Annual General Meeting, Jun 25, 2025FamiCord AG, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time.
Price Target Changed • May 06Price target increased by 8.3% to €6.50Up from €6.00, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €3.94. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.01 next year compared to a net loss per share of €0.70 last year.
Reported Earnings • May 04Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: €0.70 loss per share (further deteriorated from €0.12 loss in FY 2023). Revenue: €82.2m (up 6.6% from FY 2023). Net loss: €12.1m (loss widened €10.3m from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • Jan 09+ 3 more updatesVITA 34 AG to Report Q1, 2025 Results on May 28, 2025VITA 34 AG announced that they will report Q1, 2025 results on May 28, 2025
Major Estimate Revision • Dec 01Consensus estimates of losses per share improve by 38%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €81.0m to €82.0m. EPS estimate increased from -€0.08 per share to -€0.05 per share. Healthcare industry in Germany expected to see average net income decline 4.2% next year. Consensus price target of €6.30 unchanged from last update. Share price was steady at €4.12 over the past week.
New Risk • Nov 25New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 17% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€72.5m market cap, or US$75.5m).
Reported Earnings • Sep 01Second quarter 2024 earnings released: €0.10 loss per share (vs €0.07 loss in 2Q 2023)Second quarter 2024 results: €0.10 loss per share (further deteriorated from €0.07 loss in 2Q 2023). Revenue: €19.5m (up 6.0% from 2Q 2023). Net loss: €1.41m (loss widened 19% from 2Q 2023). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
Major Estimate Revision • Jun 09Consensus estimates of losses per share improve by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €79.1m to €81.0m. EPS estimate increased from -€0.12 per share to -€0.08 per share. Healthcare industry in Germany expected to see average net income growth of 16% next year. Consensus price target up from €5.30 to €6.00. Share price rose 3.0% to €4.86 over the past week.
Reported Earnings • Jun 05First quarter 2024 earnings released: €0.05 loss per share (vs €0.18 loss in 1Q 2023)First quarter 2024 results: €0.05 loss per share (improved from €0.18 loss in 1Q 2023). Revenue: €18.6m (up 3.6% from 1Q 2023). Net loss: €785.0k (loss narrowed 73% from 1Q 2023). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.
Price Target Changed • Jun 05Price target increased by 15% to €6.00Up from €5.21, the current price target is provided by 1 analyst. New target price is 22% above last closing price of €4.92. Stock is down 20% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.12 last year.
Breakeven Date Change • May 02No longer forecast to breakevenThe analyst covering VITA 34 no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.05m in 2024. New forecast suggests the company will make a loss of €1.50m in 2025.
お知らせ • Apr 27+ 3 more updatesVITA 34 AG to Report Q1, 2024 Results on May 31, 2024VITA 34 AG announced that they will report Q1, 2024 results on May 31, 2024
New Risk • Apr 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€78.8m market cap, or US$83.8m).
New Risk • Apr 04New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €25m Forecast net loss in 2 years: €1.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Shareholders have been diluted in the past year (10% increase in shares outstanding).
分析記事 • Apr 04Why We're Not Concerned About VITA 34 AG's (ETR:V3V) Share PriceWhen close to half the companies in the Healthcare industry in Germany have price-to-sales ratios (or "P/S") below...
New Risk • Feb 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€86.3m market cap, or US$93.1m).
分析記事 • Dec 24Revenues Tell The Story For VITA 34 AG (ETR:V3V) As Its Stock Soars 26%VITA 34 AG ( ETR:V3V ) shareholders would be excited to see that the share price has had a great month, posting a 26...
Reported Earnings • Nov 26Third quarter 2023 earnings released: €0.10 loss per share (vs €0.02 loss in 3Q 2022)Third quarter 2023 results: €0.10 loss per share (further deteriorated from €0.02 loss in 3Q 2022). Revenue: €20.4m (up 9.4% from 3Q 2022). Net loss: €1.62m (loss widened €1.41m from 3Q 2022). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 1.6% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.
分析記事 • Nov 23Is VITA 34 (ETR:V3V) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Sep 01Second quarter 2023 earnings released: €0.07 loss per share (vs €0.30 loss in 2Q 2022)Second quarter 2023 results: €0.07 loss per share (improved from €0.30 loss in 2Q 2022). Revenue: €18.4m (up 10% from 2Q 2022). Net loss: €1.19m (loss narrowed 74% from 2Q 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
分析記事 • Jul 15Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Major Estimate Revision • Jul 05Consensus EPS estimates fall by 28%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €75.0m to €76.0m. Forecast EPS reduced from -€0.09 to -€0.115 per share. Healthcare industry in Germany expected to see average net income growth of 15% next year. Consensus price target down from €9.25 to €6.81. Share price rose 2.2% to €5.64 over the past week.
New Risk • Jun 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€83.6m market cap, or US$91.2m).
New Risk • Jun 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €83.6m (US$90.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Reported Earnings • Jun 02First quarter 2023 earnings released: €0.18 loss per share (vs €0.18 loss in 1Q 2022)First quarter 2023 results: €0.18 loss per share (in line with 1Q 2022). Revenue: €17.9m (up 16% from 1Q 2022). Net loss: €2.89m (loss widened 2.8% from 1Q 2022). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance.
お知らせ • May 12Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug CandidateVita 34 AG has started enrollment in Phase I of the Tarcidomgen Kimleucel clinical trial. The drug candidate is an anti-CD19 CAR-T, a chimeric antigen receptor, and the first candidate in Vita 34's Cell & Gene Therapy (CGT) portfolio. After recent clearance by the responsible authorities and the responsible ethics committee, the start of the clinical trial under the name CARLA and the recruitment of the first patient ("First Patient In") is imminent. A total of up to ten patients are expected to be recruited for Phase I of the study, which is the usual number for this type of drug. The recruitment will take place via two clinical centers in Poland. The Management Board of Vita 34 AG expects Phase I to be completed by the end of 2023. The costs related with this phase of the trial have already taken into consideration in the guidance published for 2023. The principal investigator of the CARLA study is Prof. Grzegorz Basak, Professor and Chairman of the Department of Hematology, Transplantation and Internal Medicine at the University Hospital of Warsaw Medical University. Tarcidomgen Kimlucel is being developed through FamiCordTx, a subsidiary of Vita 34 AG that aims to develop proprietary CAR-T drug therapies. FamiCordTx has secured an exclusive license from a U.S. supplier for this purpose in the past and has optimized the technology according to European GMP standards. CAR-T therapy uses a patient's own T cells, which are genetically engineered in a laboratory to produce a protein called a chimeric antigen receptor (CAR). When the modified T-cells are returned to the patient, the CAR enables the T- cells to seek out and destroy cancer cells wherever they are in the body. According to a report by Allied Market Research, the global CAR-T cell therapy market was valued USD 1,7 billion in 2021 and is expected to reach USD 6.1 billion by 2031.
Reported Earnings • May 02Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: €1.71 loss per share (further deteriorated from €0.63 loss in FY 2021). Revenue: €68.9m (up 143% from FY 2021). Net loss: €27.1m (loss widened €23.4m from FY 2021). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 100 percentage points per year, which is a significant difference in performance.
分析記事 • Feb 17Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • Dec 03+ 4 more updatesVITA 34 AG to Report Q3, 2023 Results on Nov 21, 2023VITA 34 AG announced that they will report Q3, 2023 results on Nov 21, 2023
Major Estimate Revision • Dec 01Consensus estimates of losses per share improve by 10%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from €66.5m to €67.7m. EPS estimate increased from -€0.59 per share to -€0.53 per share. Healthcare industry in Germany expected to see average net income decline 6.2% next year. Consensus price target of €10.50 unchanged from last update. Share price fell 7.6% to €8.32 over the past week.
Reported Earnings • Nov 24Third quarter 2022 earnings released: €0.02 loss per share (vs €0.11 profit in 3Q 2021)Third quarter 2022 results: €0.02 loss per share (down from €0.11 profit in 3Q 2021). Revenue: €18.7m (up 230% from 3Q 2021). Net loss: €209.0k (down 147% from profit in 3Q 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.
Price Target Changed • Nov 16Price target decreased to €10.50Down from €12.50, the current price target is an average from 2 analysts. New target price is 17% above last closing price of €9.00. Stock is down 46% over the past year. The company is forecast to post a net loss per share of €0.59 next year compared to a net loss per share of €0.63 last year.
Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: €0.30 (vs €0.002 loss in 2Q 2021)Second quarter 2022 results: EPS: €0.30. Revenue: €16.6m (up 206% from 2Q 2021). Net loss: €4.61m (loss widened €4.60m from 2Q 2021). Over the next year, revenue is forecast to grow 48%, compared to a 3.7% growth forecast for the Healthcare industry in Germany.
お知らせ • Aug 31VITA 34 AG Revises Earnings Guidance for the Financial Year 2022VITA 34 AG revised earnings guidance for the financial year 2022. For the year, the company adjusting the forecast ranges for consolidated sales to EUR 65 to EUR 72 million (previously: EUR 68 to EUR 75 million).
お知らせ • Aug 24VITA 34 AG to Report Q2, 2022 Results on Aug 30, 2022VITA 34 AG announced that they will report Q2, 2022 results on Aug 30, 2022
お知らせ • Jun 30+ 1 more updateVITA 34 AG, Annual General Meeting, Jun 29, 2022VITA 34 AG, Annual General Meeting, Jun 29, 2022. Agenda: To consider new Chief Financial Officer; and to consider other matters.
Major Estimate Revision • Jun 07Consensus EPS estimates fall by 85%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €73.4m to €68.9m. Losses expected to increase from €0.27 per share to €0.50. Healthcare industry in Germany expected to see average net income growth of 6.5% next year. Consensus price target down from €14.00 to €13.00. Share price rose 2.3% to €11.35 over the past week.
Reported Earnings • Jun 02First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: €0.18 loss per share (down from €0.01 loss in 1Q 2021). Revenue: €15.5m (up 188% from 1Q 2021). Net loss: €2.81m (loss widened €2.77m from 1Q 2021). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 103%, compared to a 4.8% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.
お知らせ • May 25VITA 34 AG to Report Q1, 2022 Results on May 31, 2022VITA 34 AG announced that they will report Q1, 2022 results on May 31, 2022
Reported Earnings • May 02Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: €0.63 loss per share (down from €0.37 profit in FY 2020). Revenue: €28.4m (up 42% from FY 2020). Net loss: €3.67m (down 343% from profit in FY 2020). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 17% compared to a 5.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • May 02Vita 34 Ag Provides Revenue Guidance for the Financial Year 2022VITA 34 AG provided revenue guidance for the financial year 2022. For the year, the company expects consolidated revenues of between EUR 68 million and EUR 75 million for the full year 2022 (2021: EUR 28.4 million).
Price Target Changed • Apr 27Price target increased to €25.00Up from €19.10, the current price target is provided by 1 analyst. New target price is 109% above last closing price of €11.95. Stock is down 29% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year.
分析記事 • Apr 08Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?VITA 34 AG ( ETR:V3V ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in the...
Price Target Changed • Dec 18Price target increased to €21.10Up from €19.10, the current price target is an average from 2 analysts. New target price is 35% above last closing price of €15.60. Stock is up 27% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year.
分析記事 • Dec 07VITA 34 AG's (ETR:V3V) CEO Compensation Looks Acceptable To Us And Here's WhyDespite strong share price growth of 39% for VITA 34 AG ( ETR:V3V ) over the last few years, earnings growth has been...
Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS €0.14 (vs €0.18 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: €5.82m (up 7.4% from 3Q 2020). Net income: €575.0k (down 23% from 3Q 2020). Profit margin: 9.9% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Reported Earnings • Sep 01Second quarter 2021 earnings releasedThe company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: €5.44m (up 11% from 2Q 2020). Net loss: €12.0k (down 102% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 3% per year.
Major Estimate Revision • Jun 08Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from €22.0m to €21.8m. EPS estimate rose from €0.47 to €0.52. Net income forecast to grow 92% next year vs 92% growth forecast for Healthcare industry in Germany. Consensus price target of €19.10 unchanged from last update. Share price was steady at €17.05 over the past week.
お知らせ • Jun 02VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million.VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million on May 31, 2021. Transaction to be carried out by way of a contribution in kind at an exchange of 1.3 new Vita 34 shares in exchange for one (1) share of PBKM. Under the transaction, AOC Health GmbH will sell 5.743221 million shares representing 62.4% stake, Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. will sell 1.282201 million shares representing 13.93% stake and Jakub Baran will sell 0.395875 million shares representing 4.3% stake. Major PBKM shareholders have already agreed to contribute to Vita 34 a total of 6.363170 million PBKM shares (representing approximately 69.13% of the current share capital of PBKM). The combined Group will be listed on the Frankfurt Stock Exchange, with Vita 34 as the listed parent company. These shareholders include (inter alia) AOC Health GmbH, Jakub Baran, President and Chief Executive officer of the PBKM Management Board, and Tomasz Baran, Vice President and Deputy Chief Executive officer of the PBKM Management Board. The new Vita 34 shares to be issued under the Proposed Transaction shall be created by way of a capital increase in kind still to be resolved upon by Vita 34’s shareholders. For purposes of resolving the capital increase, Vita 34 will convene an extraordinary general meeting for July 13, 2021, with the ordinary annual general meeting originally scheduled for June 30, 2021 to be postponed and likely to take place in the fourth quarter of 2021. At the extraordinary general meeting, Vita 34’s share capital shall be increased by up to €12.280560 million against contribution in kind by issuing up to 12,280,560 no-par value registered shares. Completion of the Exchange Offer is subject to a number of conditions, including the achievement of a minimum acceptance level of 95% of PBKM’s outstanding shares and the absence of any material adverse change and no material adverse infringements occurring at PBKM. Transaction has been approved by the Supervisory Board of Vita 34 AG. The Management Board PBKM intends to support the Proposed Transaction and recommend to the PBKM shareholders to accept the Exchange Offer. Transaction is expected to complete by the end of October 2021. VITA 34 AG appointed ValueTrust Financial Advisors SE as an independent expert under the transaction.
Reported Earnings • Jun 01First quarter 2021 earnings releasedThe company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: €5.38m (up 15% from 1Q 2020). Net loss: €38.0k (down 110% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
お知らせ • Jun 01VITA 34 AG Provides Earnings Guidance for the Year 2021VITA 34 AG maintained guidance for 2021. The Management Board maintains its guidance for the full fiscal year 2021 of Vita 34 AG (prior to the planned merger) published in the context of the Annual Report 2020.
分析記事 • May 12Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?While VITA 34 AG ( ETR:V3V ) might not be the most widely known stock at the moment, it saw a significant share price...
Major Estimate Revision • Apr 07Consensus EPS estimates fall to €0.47The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €22.3m to €22.0m. EPS estimate also fell from €0.61 to €0.47. Net income forecast to grow 26% next year vs 16% growth forecast for Healthcare industry in Germany. Consensus price target up from €20.00 to €21.00. Share price rose 2.3% to €15.25 over the past week.
分析記事 • Apr 03Earnings Miss: VITA 34 AG Missed EPS By 29% And Analysts Are Revising Their ForecastsVITA 34 AG ( ETR:V3V ) missed earnings with its latest full-year results, disappointing overly-optimistic forecasters...
Reported Earnings • Apr 01Full year 2020 earnings released: EPS €0.37 (vs €0.18 in FY 2019)The company reported a solid full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: €20.1m (flat on FY 2019). Net income: €1.51m (up 104% from FY 2019). Profit margin: 7.5% (up from 3.7% in FY 2019). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
分析記事 • Mar 25VITA 34 AG's (ETR:V3V) Intrinsic Value Is Potentially 56% Above Its Share PriceHow far off is VITA 34 AG ( ETR:V3V ) from its intrinsic value? Using the most recent financial data, we'll take a look...
お知らせ • Mar 17+ 3 more updatesVITA 34 AG to Report Q1, 2021 Results on May 11, 2021VITA 34 AG announced that they will report Q1, 2021 results on May 11, 2021
分析記事 • Mar 10Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
分析記事 • Feb 22Here's Why VITA 34 (ETR:V3V) Can Manage Its Debt ResponsiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 10New 90-day high: €13.95The company is up 11% from its price of €12.60 on 11 November 2020. The German market is also up 11% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Healthcare industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.83 per share.
分析記事 • Feb 05Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?VITA 34 AG ( ETR:V3V ), might not be a large cap stock, but it led the XTRA gainers with a relatively large price hike...
Is New 90 Day High Low • Jan 23New 90-day high: €13.05The company is up 4.0% from its price of €12.55 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.88 per share.
分析記事 • Jan 18Can Mixed Financials Have A Negative Impact on VITA 34 AG's 's (ETR:V3V) Current Price Momentum?Most readers would already know that VITA 34's (ETR:V3V) stock increased by 4.5% over the past month. However, we...
分析記事 • Jan 02Did You Participate In Any Of VITA 34's (ETR:V3V) Fantastic 201% Return ?The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
お知らせ • Dec 19VITA 34 AG, Annual General Meeting, Jun 30, 2021VITA 34 AG, Annual General Meeting, Jun 30, 2021.
分析記事 • Dec 18How Is VITA 34's (ETR:V3V) CEO Compensated?This article will reflect on the compensation paid to Wolfgang Knirsch who has served as CEO of VITA 34 AG ( ETR:V3V...
分析記事 • Dec 01Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
